Qure.ai launches AI tools qXR and qER to spot TB, lung nodules, hemorrhages
India’s health-tech boom is finally shining a light on startups that can turn raw data into quicker care. Among the handful that have caught attention, one Bangalore-based firm is wrestling with a daily headache for radiologists: scrolling through endless scans to catch life-threatening clues. The problem feels especially acute in places where tuberculosis, hidden lung nodules and brain bleeds still show up late.
Imagine a system that could flag the most urgent images the instant they’re taken, giving clinicians a chance to step in before things get worse. That’s the idea driving the company’s newest push - two AI-powered tools, one for chest X-rays, the other for head CTs. By slipping deep-learning models into the usual workflow, they hope to cut the lag between imaging and treatment, easing pressure on already stretched radiology departments.
If it works, real-time triage might shave hours off a diagnosis and, maybe, save lives.
**Qure.ai** builds AI-driven diagnostic tools for medical imaging, including chest X-rays (qXR) and head CT scans (qER), to spot tuberculosis, lung nodules and haemorrhages. Their models aim to speed up diagnosis by triaging critical cases in real time, likely reducing radiologist workload.
Qure.ai Qure.ai builds AI-powered diagnostic tools for medical imaging, including chest X-rays (qXR) and head CT scans (qER), to detect conditions like tuberculosis, lung nodules and haemorrhages. Their deep learning models speed up diagnosis by triaging critical cases in real time, reducing radiologists' workload. Recently, Qure.ai announced plans to expand to 10,000 hospitals in the coming years.
SigTuple SigTuple combines robotics and AI via its AI100 platform to digitise microscope slides, including blood smears and urine, and analyse them. Their AI models classify different cell types, detect morphological anomalies and flag abnormalities. The AI100 product is FDA 510(k) approved, and SigTuple holds multiple patents on its AI-based screening tools.
Qure.ai just rolled out qXR for chest X-rays and qER for head CTs, tools that aim to spot TB, lung nodules or intracranial bleeds as the scan comes in. The company says its deep-learning models can push critical cases to the front of the line, which might lighten a radiologist’s day. I haven’t seen any trial numbers yet, and the piece offers no clue about how these algorithms fit into existing PACS or what the false-positive rate looks like.
India’s health-tech scene has ballooned from about $3 billion in 2020 to $7 billion in FY 2023, and analysts are penciling in a $60 billion market by FY 2028. More than 10,000 health and life startups now compete, with Qure.ai listed among the top ten AI-focused players. That growth brings both chance and crowding; whether Qure.ai can keep its edge is still up in the air.
Likewise, we don’t know how much patient outcomes or costs will shift. So the new suite is another AI option on a busy shelf - its true worth will hinge on uptake, regulatory sign-offs and solid performance data.
Related Reading
Business & Startups Oracle, NVIDIA deepen tie-up to speed sovereign AI and government digital shift
Business & Startups Skilling programs lag AI; students must prioritize aspiration and depth
Business & Startups EPAM and Cursor partner to scale AI coding for global enterprise customers
Common Questions Answered
What imaging modalities do Qure.ai's new tools qXR and qER specifically analyze?
qXR is designed to interpret chest X‑ray images, while qER focuses on head CT scans. Both tools use deep‑learning algorithms to automatically detect abnormalities such as tuberculosis, lung nodules, and intracranial haemorrhages.
How does Qure.ai claim its deep‑learning models will change radiologists' workflow for detecting tuberculosis, lung nodules, and haemorrhages?
The company says its models triage critical cases in real time, instantly flagging scans that show signs of tuberculosis, lung nodules, or intracranial haemorrhage. By highlighting the most urgent images first, radiologists can prioritize those cases and reduce overall reading time.
What expansion goal has Qure.ai set for its AI diagnostic tools, and what does this indicate about India's health‑tech sector?
Qure.ai announced plans to deploy its solutions in 10,000 hospitals over the coming years. This ambitious target reflects the rapid growth of India's health‑tech market, which has expanded from roughly $3 billion in 2020 to about $7 billion today.
What key information does the article say is missing regarding the clinical validation of qXR and qER?
The article notes that no specific data on clinical validation or real‑world performance of qXR and qER is provided. It also highlights a lack of detail on integration challenges, leaving the overall effectiveness of the tools uncertain.